MedPath

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

Conditions
Amyotrophic Lateral Sclerosis
Registration Number
NCT06069934
Lead Sponsor
Prilenia
Brief Summary

Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.

Detailed Description

ALS: Pridopidine will be given at a dose of 45 mg twice daily p.o. (or via feeding tube) over a 2-week up-titration period; followed by pridopidine 45 mg twice daily p.o. (or via feeding tube) for the remainder of the treatment period (through Week 104).

Each patient will be followed for 2 years with regularly scheduled visits. The screening and baseline visits will be performed in person; subsequent visits may occur in person or remotely. Recommended in-person visits will occur at Weeks 12, 52, 78, and end of treatment (Week 104 or early termination). If the patient is unable to complete the visits in person, these visits may also be completed remotely.

Recruitment & Eligibility

Status
NO_LONGER_AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (32)

University of Alabama at Birmingham

๐Ÿ‡บ๐Ÿ‡ธ

Birmingham, Alabama, United States

Barrow Neurological Institute

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix, Arizona, United States

University of California, San Diego Health

๐Ÿ‡บ๐Ÿ‡ธ

La Jolla, California, United States

UC Irvine

๐Ÿ‡บ๐Ÿ‡ธ

Orange, California, United States

California Pacific Medical Center - Forbes Norris MDA/ALS Research Center

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

University of Colorado Anschutz Medical Campus

๐Ÿ‡บ๐Ÿ‡ธ

Aurora, Colorado, United States

Hospital for Special Care

๐Ÿ‡บ๐Ÿ‡ธ

New Britain, Connecticut, United States

Nova Southeastern University

๐Ÿ‡บ๐Ÿ‡ธ

Fort Lauderdale, Florida, United States

Mayo Clinic Jacksonville

๐Ÿ‡บ๐Ÿ‡ธ

Jacksonville, Florida, United States

University of South Florida

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

Northwestern University

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

University of Iowa Hospitals and Clinics

๐Ÿ‡บ๐Ÿ‡ธ

Iowa City, Iowa, United States

The University of Kansas Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Kansas, United States

Massachusetts General Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Lahey Hospital Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Burlington, Massachusetts, United States

University of Massachusetts Chan Medical School

๐Ÿ‡บ๐Ÿ‡ธ

Worcester, Massachusetts, United States

Essentia Health

๐Ÿ‡บ๐Ÿ‡ธ

Duluth, Minnesota, United States

University of Minnesota

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Columbia University

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Stony Brook University Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Stony Brook, New York, United States

Mayo Clinic Rochester

๐Ÿ‡บ๐Ÿ‡ธ

Rochester, Minnesota, United States

Washington University

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

SUNY Upstate

๐Ÿ‡บ๐Ÿ‡ธ

Syracuse, New York, United States

Duke University

๐Ÿ‡บ๐Ÿ‡ธ

Durham, North Carolina, United States

OhioHealth

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Ohio, United States

Thomas Jefferson University

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Lewis Katz School of Medicine at Temple University

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Texas Neurology

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

UT Southwestern Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

Virginia Commonwealth University

๐Ÿ‡บ๐Ÿ‡ธ

Richmond, Virginia, United States

Medical College of Wisconsin

๐Ÿ‡บ๐Ÿ‡ธ

Milwaukee, Wisconsin, United States

CHALS-CCT Program, UPR-MSC

๐Ÿ‡ต๐Ÿ‡ท

San Juan, Puerto Rico

ยฉ Copyright 2025. All Rights Reserved by MedPath